-
)
hubXchange is proud to announce the return of its highly anticipated Boston Series of Life Science Xchange Roundtable Events, taking place across six focused dates in June 2025 at the Westin Waltham B ... -
)
In the rapidly advancing field of therapeutic antibody development, speed, specificity, and diversity remain crucial for successful candidate selection. Traditional methods such as hybridoma and phage ... -
)
Antibody–drug conjugates (ADCs) have emerged as “biological missiles” against cancer, achieving notable successes in multiple tumor types. For example, HER2-targeted ADCs like trastuzumab deruxtecan ( ... -
)
The rapid advancement of oligonucleotide therapeutics is pushing the boundaries of drug design, precision, and delivery. As researchers innovate new modalities and chemistries—from antisense oligonucl ... -
)
As data-intensive industries continue to scale, the pressure mounts on cloud infrastructure to deliver not just storage, but intelligent, high-throughput, cost-effective, and secure solutions. Enter f ... -
)
The U.S. life sciences industry – spanning biotechnology firms, pharmaceutical manufacturers, and research organizations – is facing unprecedented headwinds in 2025 due to new tariffs introduced by th ... -
)
The antibody-drug conjugate (ADC) development arena is experiencing a tumultuous phase marked by strategic pivots, trial disappointments, high-stakes legal clashes, and encouraging scientific wins. Re ... -
)
Isomorphic Labs, an AI-first drug design and development company spun out from Google DeepMind, has announced a landmark $600 million funding round to advance its next-generation AI drug design engine ... -
)
In a moment that will undoubtedly reverberate across the biomedical and regulatory community, Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (CBER), has announced ... -
)
Antibody-drug conjugates (ADCs) continue to gain traction as a cornerstone of targeted oncology, offering the ability to selectively deliver potent cytotoxins to tumor cells while sparing healthy tiss ... -
)
Facts about AAV producer cell lines Gene therapies hold almost unlimited promise to treat diseases that have a genetic component. Several gene therapies are commercially available, with adeno-associat ... -
)
Introduction Antibody-drug conjugates (ADCs) have revolutionized targeted cancer therapy by combining the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic agents. However, des ... -
)
Why it Matters Transferring potency assays is a complex but crucial process in the development and manufacturing of biological products, particularly in the realm of cell and gene therapies (CGTs). Th ... -
)
Hydrogels, three-dimensional polymeric networks capable of absorbing substantial amounts of water, have emerged as pivotal materials in the realm of drug delivery systems. Their structural versatility ... -
)
Introduction Antibody-drug conjugates (ADCs) have emerged as a transformative modality in oncology, enabling the targeted delivery of cytotoxic agents to tumor cells while minimizing systemic toxicity ... -
)
Case Overview: A Pioneering Treatment with Unforeseen Longevity In 2004, a four-year-old girl diagnosed with high-risk neuroblastoma was enrolled in an early-phase CAR-T clinical trial at Texas Childr ... -
)
Breakthrough in Duchenne Gene Therapy Solid Biosciences has announced promising early results from its Phase 1/2 INSPIRE DUCHENNE trial (NCT06138639) evaluating SGT-003, an investigational gene therap ... -
)
FDA Decision Expected by August 18, 2025 NOVATO, Calif., Feb. 18, 2025 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced that the U.S. Food and Drug Administration (FDA) has accepted for r ... -
)
Sarepta Therapeutics: Pioneering Genetic Medicine Sarepta Therapeutics, a biotechnology company headquartered in Cambridge, Massachusetts, is a global leader in precision genetic medicine. The company ... -
)
The biggest asset for any drug discovery organization is the ability to access and analyze insightful, contextual, and actionable data, which then informs and underpins critical decision making. New t ... -
)
Event Overview: Antibody Therapeutics Xchange | February 19, 2025 Explore the latest advancements in antibody design, engineering, and optimization. Participants will tackle pressing challenges in ant ... -
)
Optimizing Dose and Leveraging Biomarkers for Enhanced Patient Safety in Immunotherapy Trials HubXchange Immunotherapies brought together almost 40 senior-level scientists and executives from the phar ... -
)
Tumor cells have developed sophisticated mechanisms to evade the immune system, posing significant challenges to effective cancer treatment. Recent research has elucidated several key strategies emplo ... -
)
The University of Birmingham has launched Europe's first clinical trial investigating the use of an mRNA-based vaccine to combat pancreatic cancer, a significant advance in personalized cancer immunot ... -
)
In the rapidly evolving landscape of precision medicine, one of the greatest challenges lies in predicting individual patient responses to therapeutic agents. Drug efficacy and toxicity can vary widel ... -
)
The use of machine learning (ML) in the analysis of vast biological datasets is revolutionizing our approach to drug discovery, personalized medicine, and therapeutic outcome prediction. As senior sci ... -
)
Farcast Biosciences, a research solutions company and developer of the TruTumor platform—a large fragment, near-native tumor preservation and histo-culture platform enabling precision tumor microenvir ... -
)
Nanotechnology, once confined to the realm of theoretical research, is now revolutionizing biomedical science, particularly in cancer diagnostics and therapy. Nanorobots, designed with the capacity to ... -
)
BNT116, developed by BioNTech, is an advanced mRNA-based therapeutic vaccine designed specifically to target non-small cell lung cancer (NSCLC). This vaccine falls within the broader scope of BioNTech ... -
)
In the dynamic and rapidly evolving field of antibody therapeutics, the ability to identify targets with optimal therapeutic windows is a critical determinant of clinical success. The therapeutic wind ...
NEWS XCHANGE
